公开(公告)号：AU7491400A

公开(公告)日：2001-04-17

申请号：AU7491400

申请日：2000-09-15

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  RITTER KURT ,  RAFFERTY PAUL ,  GALLAY STEPHEN ST ,  CALDERWOOD DAVID

IPC: A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/55 ,  A61K38/00 ,  A61P1/18 ,  A61P3/10 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P15/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P33/02 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C07D471/04 ,  C07D487/04 ,  C07F9/6561 ,  C07D491/04 ,  C07D498/04 ,  A61K31/4353 ,  A61K31/551 ,  C07D239/00 ,  C07D209/00 ,  C07D237/00 ,  C07D231/00 ,  C07D221/00 ,  C07D243/00

Abstract: The present invention is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.

公开(公告)号：AU5179000A

公开(公告)日：2000-12-28

申请号：AU5179000

申请日：2000-06-02

Applicant: BASF AG

Inventor： RAFFERTY PAUL ,  CALDERWOOD DAVID ,  ARNOLD LEE D ,  PASCUAL BEATRIZ GONZALEZ ,  MATINEZ JOSE L ORTEGO ,  VEGA MARIA J PEREZ DE ,  FERNANDEZ ISABEL F

IPC: C07D265/36 ,  A61K31/42 ,  A61K31/425 ,  A61K31/437 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61P1/00 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P9/10 ,  A61P11/16 ,  A61P15/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P43/00 ,  C07D20060101 ,  C07D279/16 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/00 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

Abstract: Q is -N=or CR 2 X is S, O or NOR 3 Y is -O-, -S-, -SO- or -SO 2 - R and R 1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R 2 is H or a substituent R 3 is H, or -C(O)R 4 R 4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

公开(公告)号：AT247657T

公开(公告)日：2003-09-15

申请号：AT00963554

申请日：2000-09-15

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  WISHART NEIL ,  RAFFERTY PAUL ,  RITTER KURT ,  ARNOLD LEE D ,  FRIEDMAN MICHAEL M

IPC: A61K31/519 ,  A61K31/5377 ,  A61K38/22 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P5/14 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/00 ,  A61P13/12 ,  A61P15/16 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/22 ,  A61P33/02 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07D239/00 ,  C07D231/00

Abstract: The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

公开(公告)号：AU753555C

公开(公告)日：2003-07-03

申请号：AU6048499

申请日：1999-09-17

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  RAFFERTY PAUL ,  ARNOLD LEE D ,  JOHNSTON DAVID N

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：AU752474B2

公开(公告)日：2002-09-19

申请号：AU6047599

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  JOHNSTON DAVID N ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：HU0200403A2

公开(公告)日：2002-06-29

申请号：HU0200403

申请日：1999-09-17

Applicant: BASF AG

Inventor： ARNOLD LEE D ,  CALDERWOOD DAVID ,  HIRST GAVIN C ,  RITTER KURT ,  WISHART NEIL

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：ZA200102201B

公开(公告)日：2002-03-15

申请号：ZA200102201

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE ,  GAVIN MAZDIYASNI HORMOZ HIRST ,  DENG BOJUAN ,  JOHNSTON DAVID N ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  C07D ,  A61K

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：PL346700A1

公开(公告)日：2002-02-25

申请号：PL34670099

申请日：1999-09-17

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  RAFFERTY PAUL ,  ARNOLD LEE D ,  JOHNSTON DAVID N

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：ID29028A

公开(公告)日：2001-07-26

申请号：ID20010652

申请日：1999-09-17

Applicant: BASF AG

Inventor： HIRST GAVIN C ,  CALDERWOOD DAVID ,  MUNSCHAUER RAINER ,  ARNOLD LEE D ,  JOHNSTON DAVID N ,  RAFFERTY PAUL ,  ARNOLD LEE D

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P9/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561 ,  C07F9/6584 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

公开(公告)号：DE60004685D1

公开(公告)日：2003-09-25

申请号：DE60004685

申请日：2000-09-15

Applicant: BASF AG

Inventor： HIRST C ,  CALDERWOOD DAVID ,  WISHART NEIL ,  RAFFERTY PAUL ,  RITTER KURT ,  ARNOLD D ,  FRIEDMAN M

IPC: A61K31/519 ,  A61K31/5377 ,  A61K38/22 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P5/14 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/00 ,  A61P13/12 ,  A61P15/16 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/04 ,  A61P31/22 ,  A61P33/02 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00 ,  C07D487/04 ,  C07F9/6561

Abstract: The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.